Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Part of paid clinical trials in Miami, Florida.

Sponsor
Rodolfo Alejandro
Study ID
NCT01999361
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Myfortic — DRUG
    treatment with myfortic

Study Details

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

Key Dates

Start date
Jan 31, 2009
Status verified
Mar 2026
Primary completion
Jan 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Myfortic treatment
    Treatment with Myfortic

Primary Outcome Measure

allosensitization after complete islet graft loss [ Time Frame: 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes Research InstituteMiamiFlorida33136
Rodolfo Alejandro, MD
[email protected]
305-243-5321
Ana M Alvarez, APRN
[email protected]
305 243-3389
Rodolfo Alejandro, MD (PRINCIPAL_INVESTIGATOR)
David A Baidal, MD (SUB_INVESTIGATOR)

Find similar trials in Miami, FL

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Diabetes Research Institute· Miami, FL

Related Studies